Isavuconazonium sulfate is a Small Molecule owned by Basilea Pharmaceutica, and is involved in 42 clinical trials, of which 40 were completed, 1 is ongoing, and 1 is planned.

Isavuconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P450 (CYP) dependent enzyme lanosterol 14a-demethylase, which is responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.

The revenue for Isavuconazonium sulfate is expected to reach a total of $3.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Isavuconazonium sulfate NPV Report.

Isavuconazonium sulfate was originated by F. Hoffmann-La Roche and is currently owned by Basilea Pharmaceutica. Astellas Pharma is the other company associated in development or marketing of Isavuconazonium sulfate.

Isavuconazonium sulfate Overview

Isavuconazonium sulfate (Cresemba, BAL-4815, isavuconazole) is an azole anti-fungal agent. It is formulated as hard gelatin capsules for oral administration and injection powder for solution for intravenous administration. It is indicated for the treatment of invasive aspergillosis and invasive mucormycosis for whom amphotericin B is inappropriate.

It is under development for the treatment of fungal infections such as invasive aspergillosis, chronic lung aspergilosis, mucormycosis, and cryptococcosis. The drug candidate is also under development for Invasive aspergillosis and mucormycosis in pediatric patients. The drug candidate is also under development for the prevention of COVID-19-associated Pulmonary Aspergillosis. The drug candidate was also under development for the treatment of candidemia and other invasive Candida infections.

Astellas Pharma Overview

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a wide range of urological diseases, infectious diseases, cancer, nephrology, and metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline possesses drug candidates for the treatment of urothelial cancer; gastric cancer; gastroesophageal junction cancer; anemia associated with chronic kidney disease (CKD) in dialysis; Rheumatoid arthritis and non-dialysis patients; menopause-related vasomotor symptoms (MR-VMS) such as hot flashes and night sweats; and acute myeloid leukemia (AML), among others. It operates in the Americas, Australia, Europe, and Asia and Oceania through a network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY1,296,163 million for the fiscal year ended March 2022 (FY2022), an increase of 3.7% over FY2021. In FY2022, the company’s operating margin was 12.4%, compared to an operating margin of 11.7% in FY2021. In FY2022, the company recorded a net margin of 9.6%, compared to a net margin of 9.7% in FY2021. The company reported revenues of JPY380,394 million for the second quarter ended September 2022, a decrease of 0.4% over the previous quarter.

Quick View – Isavuconazonium sulfate

Report Segments
  • Innovator (NME)
Drug Name
  • Isavuconazonium sulfate
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.